]>
IRCT20200825048515N45 IRCT 2021-10-20 Esfahan University of Medical Sciences The effect of symbiotic familact 2 plus on ventilator-associated pneumonia Evaluation of the effect of symbiotic familact 2 plus on ventilator-associated pneumonia (VAP) in patients admitted to the intensive care unit 2021-10-23 anticipated 80 Complete https://irct.ir/trial/59056 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, 80 eligible patients are randomly selected. For this, the letter A is written on 40 sheets, and the letter B is written on 40 sheets and each of them is placed in an envelope. Each patient is then asked to choose one of the envelopes. Depending on the selected envelope, the patient is assigned to one of two groups, Blinding description: In order to observe blindness, the drugs are prepared in the same shape and amount before the intervention and are coded and given to the ICU nurse. They prescribe them without knowing the type of each drug. Therefore, the patient, the patient, the person recording the clinical and baseline information of the patients as well as the statistical analyst will not be aware of the type of intervention. 3 Pneumonia. Intervention 1: Intervention group: In this group, oral FamiLact synbiotic (probiotic + prebiotic) (Biology fermentation Company) 2 tablets daily every 12 hours will be prescribed. Intervention 2: Control group: In this group, 2 oral placebo drugs will be prescribed every 12 hours. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information
public Atousa Hakamifard
Department of Infectious Diseases and Tropical Medicine, Al-Zahra Hospital, Hezar Jarib Street.
Isfahan Iran (Islamic Republic of) 8174673461 +98 31 3620 2020 atousahakamifard@yahoo.com Esfahan University of Medical Sciences scientific Atousa Hakamifard
Department of Infectious Diseases and Tropical Medicine, Al-Zahra Hospital, Hezar Jarib Street.
Isfahan Iran (Islamic Republic of) 8174673461 +98 31 3620 2020 atousahakamifard@yahoo.com Esfahan University of Medical Sciences Iran (Islamic Republic of) Hospitalized in the intensive care unit under mechanical ventilation Satisfaction to participate in the study no limit no limit Both Pulmonary infection before starting mechanical ventilation J18 Pneumonia, unspecified organism Treatment - Drugs Placebo Intervention group: In this group, oral FamiLact synbiotic (probiotic + prebiotic) (Biology fermentation Company) 2 tablets daily every 12 hours will be prescribed. Control group: In this group, 2 oral placebo drugs will be prescribed every 12 hours. Incidence of pneumonia. Timepoint: Two weeks after the start of the intervention. Method of measurement: Based on the patient's symptoms and the result of sputum smear test. The length of stay in the ICU. Timepoint: Two weeks after the start of the intervention. Method of measurement: Record the number of days. Duration of connection to the ventilator. Timepoint: Two weeks after the start of the intervention. Method of measurement: Record the number of days. Isfahan University of Medical Sciences Approved 2020-11-26 Ethics committee of Isfahan University of Medical Sciences Street address Isfahan University of Medical Sciences, Hezar Jarib Ave., Azadi Sq Isfahan Isfehan Iran (Islamic Republic of)